Philippines Clinical Nutrition for Chronic Kidney Diseases Market Report 2023 to 2030

Philippines Clinical Nutrition for Chronic Kidney Diseases Market Analysis

$ 3999

Philippines Clinical Nutrition for Chronic Kidney Diseases Market was valued at $3.50 Mn in 2023 and is predicted to grow at a CAGR of 6.53% from 2023 to 2030, to $5.40 Mn by 2030. The key drivers of this industry include the rising prevalence of CKD, increased awareness and education, and advancements in nutritional science. The industry is primarily dominated by Abbott Nutrition, Pfizer Inc., Bayer AG, and Nestlé Health Science among others.

ID: IN10PHPH568 CATEGORY: Pharmaceuticals GEOGRAPHY: Phillipines AUTHOR: Sarita Yadav

Buy Now

Philippines Clinical Nutrition for Chronic Kidney Diseases Market Executive Summary

Philippines Clinical Nutrition for Chronic Kidney Diseases Market was valued at $3.50 Mn in 2023 and is predicted to grow at a CAGR of 6.53% from 2023 to 2030, to $5.40 Mn by 2030.

Chronic kidney disease (CKD) is a gradual loss of kidney function over at least three months, often progressing silently due to the absence of early symptoms. The main causes include diabetes and high blood pressure, though family history and other conditions also contribute. As CKD advances through stages, it may necessitate dialysis or a kidney transplant and is associated with increased risks of heart disease, stroke, and bone issues. Management focuses on slowing disease progression, symptom management, and preventing complications through dietary changes, medications, and blood pressure control. Key dietary adjustments include moderating protein intake, managing fluid levels, controlling electrolytes like sodium, potassium, and phosphorus, and ensuring sufficient calorie intake to avoid malnutrition. Early detection and screening are crucial for those at risk.

The prevalence of chronic kidney disease (CKD) in South Africa is estimated at 10.7%, according to the International Society of Nephrology (ISN) Global Health Atlas survey. However, estimates vary widely from 2% to 23.9%, reflecting differences in study design and CKD definitions. As of December 2020, 8,734 patients were receiving chronic dialysis or had undergone transplantation, with a prevalence of 146 per Mn population.

The market therefore is driven by significant factors like the rising prevalence of CKD, increased awareness and education, and advancements in nutritional science. However, the high cost of treatment limited healthcare infrastructure, and scarcity of qualified dietitians, restrict the growth and potential of the market.

Prominent players in this field are Abbott Nutrition, Pfizer Inc., Bayer AG, and Nestlé Health Science among others.

Philippines Clinical Nutrition for Chronic Kidney Diseases Market Report 2023 to 2030

Market Dynamics

Market Growth Drivers

Increasing CKD Prevalence: The Philippines has seen a rise in CKD cases due to diabetes, hypertension, and lifestyle factors, prompting demand for tailored clinical nutrition solutions. Estimates indicate around 7 Mn Filipinos have CKD, with one new case every hour according to the NKTI, making CKD the fourth leading cause of death in the country, thus driving the market.

Growing Awareness and Education: There is a heightened awareness among healthcare professionals and the public about the role of nutrition in managing CKD. Educational initiatives and awareness campaigns are encouraging patients to seek nutritional guidance, thus boosting the demand for clinical nutrition products.

Advancements in Nutritional Science: Ongoing research and development in nutritional science led to the introduction of innovative and effective clinical nutrition products specifically designed for CKD patients. These advancements help in meeting the unique dietary needs of CKD patients, driving market demand.

Market Restraints

High Cost of Treatment: A significant portion of the population in the Philippines faces economic challenges, limiting their ability to afford specialized clinical nutrition products and services. This financial barrier can hinder market growth and access to essential nutrition therapy for CKD patients.

Limited Healthcare Infrastructure: The healthcare infrastructure in the Philippines, especially in rural areas, may be inadequate, affecting the distribution and accessibility of clinical nutrition products. This uneven distribution of healthcare services can limit the reach of CKD-specific nutritional interventions.

Scarcity of Qualified Dietitians: There is a shortage of healthcare professionals, including dietitians specialized in CKD nutrition, in the Philippines. This scarcity restricts patients' access to expert nutritional counseling and tailored dietary management, impacting the effective implementation of clinical nutrition therapies.

Regulatory Landscape and Reimbursement Scenario

In the Philippines, the regulatory landscape for CKD-specific clinical nutrition is managed by the Food and Drug Administration (FDA) and the Department of Health (DOH). The FDA ensures the safety, efficacy, and quality of specialized dietary products for CKD management through stringent guidelines on labeling, safety testing, and product approval. Concurrently, the DOH sets broader healthcare policies and defines the scope of practice for dietitians, focusing on the licensing and regulation of dietitians/nutritionists to ensure proper medical nutrition therapy for CKD patients.

Reimbursement for CKD-specific clinical nutrition in the Philippines is gradually evolving. PhilHealth, the national health insurance program, provides some coverage for consultations with licensed dietitians/nutritionists, though coverage for specific CKD nutritional products remains limited and plan-dependent. Private health insurance plans also offer varying levels of coverage for CKD nutritional interventions, including dietitian consultations and specific products, but widespread and comprehensive coverage is not yet commonplace.

Competitive Landscape

Key Players

Here are some of the major key players in the Philippines Clinical Nutrition for Chronic Kidney Diseases Market:

Abbott Nutrition
Pfizer Inc.
Bayer AG
Nestlé Health Science
Otsuka Pharmaceutical
Mead Johnson & Company, LLC
Danone S.A.
Victus, Inc.
B. Braun Melsungen AG
Fresenius Kabi AG

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Philippines Clinical Nutrition for Chronic Kidney Diseases Market Segmentation

Product

Oral Nutrition
Parenteral Nutrition
Enteral Feeding Formulas

Stages

Adult
Paediatric

Sales Channel

Online
Retail
Institutional Sales

End-User

Hospitals
Homecare
Specialty Clinics
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.